Health Canada to review AstraZeneca’s COVID-19 prevention drug – National


    AstraZeneca has asked Health Canada to review a new long-acting antibody combination that could be used to prevent symptomatic COVID-19.

    If approved, it would be the first antibody protection of its kind in Canada.

    Read more:
    AstraZeneca COVID-19 drug prevents severe disease if given early, company says

    The company says its clinical trials showed the antibody treatment was well tolerated and reduced the risk of developing symptomatic COVID-19 by 77 per cent compared to a placebo.

    AstraZeneca Canada says it could be a good option for vulnerable populations who aren’t able to develop a strong protective response from a vaccine.

    Click to play video: 'Health Canada considers Merck’s experimental COVID-19 drug'

    Health Canada considers Merck’s experimental COVID-19 drug

    Health Canada considers Merck’s experimental COVID-19 drug – Oct 4, 2021

    The company says preliminary findings show the antibodies neutralize recent COVID-19 variants, including the Delta and Mu variants.

    Story continues below advertisement

    Health Canada has said all COVID-19 vaccine and drug submissions will be prioritized and reviewed on an expedited timeline.

    Read more:
    AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug

    © 2021 The Canadian Press


    Source link

    Recent Articles